


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:17Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406441" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406441</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>orphjrdis</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id><journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id><journal-id journal-id-type="pmc-domain-id">401</journal-id><journal-id journal-id-type="pmc-domain">orphjrdis</journal-id><journal-title-group><journal-title>Orphanet Journal of Rare Diseases</journal-title></journal-title-group><issn pub-type="epub">1750-1172</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406441</article-id><article-id pub-id-type="pmcid-ver">PMC12406441.1</article-id><article-id pub-id-type="pmcaid">12406441</article-id><article-id pub-id-type="pmcaiid">12406441</article-id><article-id pub-id-type="pmid">40898332</article-id><article-id pub-id-type="doi">10.1186/s13023-025-04006-6</article-id><article-id pub-id-type="publisher-id">4006</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Genetic and clinical features of hereditary transthyretin amyloidosis: a decade of experience at a Japanese referral center</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9657-5324</contrib-id><name name-style="western"><surname>Nomura</surname><given-names initials="T">Toshiya</given-names></name><address><email>caramelbox0106@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Misumi</surname><given-names initials="Y">Yohei</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tasaki</surname><given-names initials="M">Masayoshi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamakawa</surname><given-names initials="S">Shiori</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Taguchi</surname><given-names initials="T">Tomoaki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Obayashi</surname><given-names initials="K">Konen</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yamashita</surname><given-names initials="T">Taro</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ando</surname><given-names initials="Y">Yukio</given-names></name><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ueda</surname><given-names initials="M">Mitsuharu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02cgss904</institution-id><institution-id institution-id-type="GRID">grid.274841.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0660 6749</institution-id><institution>Department of Neurology, Graduate School of Medical Sciences, </institution><institution>Kumamoto University, </institution></institution-wrap>1-1-1 Honjo, Kumamoto, 860-0811 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vgs9327</institution-id><institution-id institution-id-type="GRID">grid.411152.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 0407 1295</institution-id><institution>Amyloidosis center, </institution><institution>Kumamoto University Hospital, </institution></institution-wrap>Kumamoto, Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02cgss904</institution-id><institution-id institution-id-type="GRID">grid.274841.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0660 6749</institution-id><institution>Department of Clinical Biosciences, Graduate School of Health Sciences, </institution><institution>Kumamoto University, </institution></institution-wrap>Kumamoto, Japan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02cgss904</institution-id><institution-id institution-id-type="GRID">grid.274841.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0660 6749</institution-id><institution>Department of Morphological and Physiological Sciences, Graduate School of Health Sciences, </institution><institution>Kumamoto University, </institution></institution-wrap>Kumamoto, Japan </aff><aff id="Aff5"><label>5</label>Department of Neurology, Soyo Hospital, Kumamoto, Japan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01tqqny90</institution-id><institution-id institution-id-type="GRID">grid.411871.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0647 5488</institution-id><institution>Department of Amyloidosis Research, </institution><institution>Nagasaki International University, </institution></institution-wrap>Nagasaki, Japan </aff><aff id="Aff7"><label>7</label>Department of Amyloidosis Supporting Center, Sugimura Hospital, Kumamoto, Japan </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue-id pub-id-type="pmc-issue-id">478503</issue-id><elocation-id>474</elocation-id><history><date date-type="received"><day>2</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>18</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="13023_2025_Article_4006.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Hereditary transthyretin (ATTRv) amyloidosis is a rare, intractable genetic disorder caused by mutations in the transthyretin (<italic toggle="yes">TTR</italic>) gene. More than 150 <italic toggle="yes">TTR</italic> mutations have been identified, along with genotype-phenotype correlations. Early diagnosis is critical to facilitate the timely initiation of disease-modifying therapies.</p></sec><sec><title>Objective</title><p id="Par2">To characterize the genetic and clinical features of ATTRv amyloidosis at our referral center.</p></sec><sec><title>Methods</title><p id="Par3">A total of 6,201 <italic toggle="yes">TTR</italic> genetic tests were conducted at Kumamoto University Hospital over a ten-year period and revealed 289 mutations, including 235 symptomatic cases, which were analyzed in this study.</p></sec><sec><title>Results</title><p id="Par4">In a cohort of 235 patients with symptomatic ATTRv amyloidosis, 46 <italic toggle="yes">TTR</italic> mutations were identified. The genotypes were distributed as follows: V30M in endemic areas (7.7%), V30M in non-endemic areas (48.5%), and non-V30M mutations (43.8%). The mean age of onset was lowest for patients with V30M in endemic areas (42.4&#8201;&#177;&#8201;15.6 years) and higher for those with non-V30M mutations (60.6&#8201;&#177;&#8201;14.6 years) and V30M in non-endemic areas (64.5&#8201;&#177;&#8201;11.9 years). Family history was present in 93.3% of V30M cases in endemic areas but absent in 42.0% of V30M cases in non-endemic areas and 57.5% of non-V30M cases. Polyneuropathy was the predominant initial symptom, affecting 73.7% of endemic V30M cases, 54.3% of non-endemic V30M cases, and 34.6% of non-V30M cases. Diagnosis occurred earlier in patients with V30M in endemic areas than in other groups. Notably, delayed diagnosis has been observed in patients presenting with carpal tunnel syndrome or polyneuropathy.</p></sec><sec><title>Conclusions</title><p id="Par5">These findings demonstrate that patients with V30M in non-endemic areas and those with non-V30M mutations are more prevalent than previously recognized and that their genetic and clinical characteristics exhibit considerable diversity.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Amyloid</kwd><kwd>Transthyretin</kwd><kwd>Hereditary transthyretin amyloidosis</kwd><kwd>Endemic areas</kwd><kwd>Non-endemic areas</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006400</institution-id><institution>Alnylam Pharmaceuticals</institution></institution-wrap></funding-source><award-id>Alnylam Pharmaceuticals</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Institut National de la Sant&#233; et de la Recherche M&#233;dicale (INSERM) 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par6">Hereditary transthyretin (ATTRv) amyloidosis is a rare and fatal genetic disorder caused by mutations in the transthyretin (<italic toggle="yes">TTR</italic>) gene. The disease is characterized by a wide spectrum of clinical manifestations, including sensorimotor polyneuropathy, autonomic dysfunction, cardiomyopathy, and gastrointestinal symptoms [<xref ref-type="bibr" rid="CR1">1</xref>]. First described by Andrade in Portugal, subsequent cases were identified in Japan and Sweden, with the V30M mutation in <italic toggle="yes">TTR</italic> being a prevalent finding in these endemic regions [<xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR5">5</xref>]. Although once thought to be restricted to endemic areas such as Portugal, Japan, and Sweden, ATTRv amyloidosis is now known to occur globally, with more than 150 pathogenic <italic toggle="yes">TTR</italic> mutations reported [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par7">Genotype-phenotype correlations have provided insights into disease variability. The V30M mutation, the most frequently identified mutation, exhibits distinct geographic differences in age of onset and penetrance between endemic and non-endemic regions [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Non-V30M mutations are associated with various phenotypes, including neuropathy-dominant, cardiomyopathy-dominant, mixed phenotypes, and oculoleptomeningeal-dominant forms [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par8">Recent advancements in disease-modifying therapies, such as liver transplantation, and novel pharmacological interventions, such as TTR tetramer stabilizers and <italic toggle="yes">TTR</italic> gene silencing therapies, have significantly improved the prognosis and quality of life of patients [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>]. Nevertheless, phenotypic heterogeneity continues to pose challenges for early diagnosis, which is crucial for effective treatment.</p><p id="Par9">To elucidate genotype-phenotype variations, this study analyzed the genetic and clinical profiles of patients with ATTRv amyloidosis diagnosed at the Amyloidosis Center, Kumamoto University Hospital.</p></sec><sec id="Sec2"><title>Patients and methods</title><sec id="Sec3"><title>Patients</title><p id="Par10">A total of 6,201 <italic toggle="yes">TTR</italic> genetic tests were performed on individuals at the Amyloidosis Center, Kumamoto University Hospital, from April 1, 2013, to March 31, 2023. The cohort included individuals suspected of having ATTRv amyloidosis or requiring differentiation from ATTRwt amyloidosis among those diagnosed with ATTR amyloidosis. <italic toggle="yes">TTR</italic> mutations were detected in 289 individuals, of whom 235 were symptomatic, and 54 were asymptomatic carriers. This retrospective study focused on the clinical and genetic characteristics of 235 patients with symptomatic ATTRv amyloidosis.</p></sec><sec id="Sec4"><title>Methods</title><p id="Par11">This study examined the clinical data of 235 patients with ATTRv amyloidosis, focusing on mutation types, patient numbers, geographic distribution by variant, age at diagnosis, sex, initial symptoms, time from onset to diagnosis, endemic versus non-endemic origins, and family history.</p><p id="Par12">Additionally, this study analyzed blood data, including serum M-protein and serum free light chains (FLCs), as well as image data, including 99mTc-PYP scintigraphy, based on the request forms received from 2020 to 2023. Myocardial PYP uptake was assessed using a semi-quantitative visual grading system (Grade 0: no uptake and normal bone uptake; Grade 1: uptake less than rib uptake; Grade 2: uptake equal to rib uptake; Grade 3: uptake greater than rib uptake with mild or absent rib uptake). Grade 2 or 3 myocardial uptake was defined as 99mTc-PYP-positive uptake in the heart [<xref ref-type="bibr" rid="CR18">18</xref>]. TTR gene analysis was performed according to previously established protocols [<xref ref-type="bibr" rid="CR19">19</xref>]. This study also assessed the detection rate of ATTR amyloid deposits in biopsied tissue samples obtained from 210 patients. Pathological evaluations included Congo red staining and immunostaining with antibodies specific to amyloid A, AL &#954; (&#954; 116&#8211;133), AL &#955; (&#955; 118&#8211;134), and TTR 115&#8211;124, as described in previous studies [<xref ref-type="bibr" rid="CR19">19</xref>].</p></sec><sec id="Sec5"><title>Statistical analysis</title><p id="Par13">Descriptive analyses were conducted for patient characteristics, with categorical data summarized as numbers and proportions (%) and continuous data presented as means with standard deviations (SD). All statistical analyses and graphical representations in this study were performed using Microsoft Excel 2021 (Microsoft Corporation, Redmond, WA, USA), the &#8220;meta&#8221; package in R Statistical Software (version 4.1.3), and RStudio.</p></sec></sec><sec id="Sec6"><title>Results</title><p id="Par14">In this study, 46 <italic toggle="yes">TTR</italic> gene mutations were identified in 235 symptomatic ATTRv amyloidosis patients, including V30M, A19D, P24S, S50I, and T60A mutations (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). V30M was the most common mutation, present in 132 patients (56.2%), predominantly in non-endemic areas (86.4%) compared to endemic regions (13.6%). Non-V30M mutations accounted for 43.8% of the cases (<italic toggle="yes">n</italic>&#8201;=&#8201;103), with S50I and T60A being the most frequently observed variants. These findings highlight the extensive genetic variability associated with ATTRv amyloidosis.</p><p id="Par15">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Mutation landscape in ATTRv amyloidosis. This figure illustrates the distribution of <italic toggle="yes">TTR</italic> mutations in 235 patients with symptomatic ATTRv amyloidosis. The analysis highlights the relative proportions of V30M mutations in endemic and non-endemic areas and non-V30M mutations, emphasizing the genetic diversity of the cohort</p></caption><graphic id="d33e391" position="float" orientation="portrait" xlink:href="13023_2025_4006_Fig1_HTML.jpg"/></fig>
</p><p id="Par16">The onset age of ATTRv amyloidosis showed significant variation: 42.4&#8201;&#177;&#8201;15.6 years for endemic V30M, 64.5&#8201;&#177;&#8201;11.9 years for non-endemic V30M, and 60.6&#8201;&#177;&#8201;14.6 years for non-V30M patients. Gender distribution differed across groups, with a female predominance in endemic V30M (0.6:1) and male predominance in non-endemic V30M (3.2:1) and non-V30M (1.9:1) (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Family history was present in 93.3% of endemic V30M cases but was less frequent in non-endemic V30M (42.0%) and non-V30M (57.5%) cases (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref> and Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par17">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic and clinical characteristics of ATTRv amyloidosis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">V30M, endemic</th><th align="left" colspan="1" rowspan="1">V30M, non-endemic</th><th align="left" colspan="1" rowspan="1">Non-V30M</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Patients, n (%)</td><td align="left" colspan="1" rowspan="1">18 (7.7%)</td><td align="left" colspan="1" rowspan="1">114 (48.5%)</td><td align="left" colspan="1" rowspan="1">103 (43.8%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Age, mean&#8201;&#177;&#8201;SD (years)</td><td align="left" colspan="1" rowspan="1">46.1&#8201;&#177;&#8201;14.5</td><td align="left" colspan="1" rowspan="1">68.9&#8201;&#177;&#8201;11.3</td><td align="left" colspan="1" rowspan="1">61.2&#8201;&#177;&#8201;13.6</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male</td><td align="left" colspan="1" rowspan="1">7 (38.9%)</td><td align="left" colspan="1" rowspan="1">87 (76.3%)</td><td align="left" colspan="1" rowspan="1">67 (65%)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td align="left" colspan="1" rowspan="1">11 (61.1%)</td><td align="left" colspan="1" rowspan="1">27 (23.7%)</td><td align="left" colspan="1" rowspan="1">36 (35%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Family history, %</td><td align="left" colspan="1" rowspan="1">93.3%</td><td align="left" colspan="1" rowspan="1">42%</td><td align="left" colspan="1" rowspan="1">57.5%</td></tr><tr><td align="left" colspan="1" rowspan="1">Onset age, mean&#8201;&#177;&#8201;SD (years)</td><td align="left" colspan="1" rowspan="1">42.4&#8201;&#177;&#8201;15.6</td><td align="left" colspan="1" rowspan="1">64.5&#8201;&#177;&#8201;11.9</td><td align="left" colspan="1" rowspan="1">60.6&#8201;&#177;&#8201;14.6</td></tr><tr><td align="left" colspan="1" rowspan="1">Time from onset to diagnosis, mean&#8201;&#177;&#8201;SD (years)</td><td align="left" colspan="1" rowspan="1">2.7&#8201;&#177;&#8201;1.7</td><td align="left" colspan="1" rowspan="1">4.6&#8201;&#177;&#8201;4.5</td><td align="left" colspan="1" rowspan="1">3.6&#8201;&#177;&#8201;3.7</td></tr></tbody></table><table-wrap-foot><p>This table presents the demographic and clinical characteristics of symptomatic ATTRv amyloidosis, classified by TTR mutation type</p></table-wrap-foot></table-wrap>
</p><p id="Par18">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Family history patterns. The figure depicts the distribution of family history among the 235 patients with symptomatic ATTRv amyloidosis. Categories include confirmed family history (black boxes), absence of family history (gray boxes), and unknown family history (white boxes), highlighting hereditary trends across different genetic mutations</p></caption><graphic id="d33e506" position="float" orientation="portrait" xlink:href="13023_2025_4006_Fig2_HTML.jpg"/></fig>
</p><p id="Par19">Figure <xref rid="Fig3" ref-type="fig">3</xref> depicts the distribution of initial symptoms among patients with symptomatic ATTRv amyloidosis, classified by <italic toggle="yes">TTR</italic> mutation type. Polyneuropathy was the most common symptom observed in 73.7% of endemic V30M cases, 54.3% of non-endemic V30M cases, and 34.6% of non-V30M cases. Secondary initial symptoms differed significantly among the mutation groups, with arrhythmia being more frequent in endemic V30M cases, ocular involvement in non-endemic V30M cases, and cardiomyopathy in non-V30M cases. Additionally, Table&#160;<xref rid="Tab1" ref-type="table">1</xref> presents the association between each genetic mutation and its corresponding clinical symptoms. Our cohort included neuropathy-dominant, cardiomyopathy-dominant, mixed, and oculoleptomeningeal-dominant phenotypes. These findings elucidate the clinical heterogeneity associated with specific mutations (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref><bold>and</bold> Table&#160;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par20">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Clinical presentation of initial symptoms. This figure shows the initial symptoms observed in the 235 patients with symptomatic ATTRv amyloidosis. Patients are categorized based on their genetic mutations as follows: V30M in endemic areas (black boxes), V30M in non-endemic areas (gray boxes), and non-V30M mutations (white boxes)</p></caption><graphic id="d33e535" position="float" orientation="portrait" xlink:href="13023_2025_4006_Fig3_HTML.jpg"/></fig>
</p><p id="Par21">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Association between genotype and phenotype</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">genotype</th><th align="left" colspan="1" rowspan="1">Number of patients</th><th align="left" colspan="1" rowspan="1">phenotype</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">V30M, non- endemic</td><td align="left" colspan="1" rowspan="1">114</td><td align="left" colspan="1" rowspan="1"><p>polyneuropathy (main), ocular involvement, cardiomyopathy,</p><p>carpal tunnel syndrome, autonomic dysfunction, arrhythmia,</p><p>renal impairment</p></td></tr><tr><td align="left" colspan="1" rowspan="1">V30M, endemic</td><td align="left" colspan="1" rowspan="1">18</td><td align="left" colspan="1" rowspan="1"><p>polyneuropathy (main), arrhythmia, autonomic dysfunction,</p><p>renal impairment</p></td></tr><tr><td align="left" colspan="1" rowspan="1">S50I</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">cardiomyopathy, polyneuropathy, others</td></tr><tr><td align="left" colspan="1" rowspan="1">T60A</td><td align="left" colspan="1" rowspan="1">8</td><td align="left" colspan="1" rowspan="1">cardiomyopathy, polyneuropathy, arrhythmia, renal impairment</td></tr><tr><td align="left" colspan="1" rowspan="1">E61K</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">cardiomyopathy, polyneuropathy, autonomic dysfunction</td></tr><tr><td align="left" colspan="1" rowspan="1">I107V</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">polyneuropathy, carpal tunnel syndrome</td></tr><tr><td align="left" colspan="1" rowspan="1">Y114C</td><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">polyneuropathy, autonomic dysfunction, ocular involvement, arrhythmia</td></tr><tr><td align="left" colspan="1" rowspan="1">P24S</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">G47R</td><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">autonomic dysfunction</td></tr><tr><td align="left" colspan="1" rowspan="1">A25T</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">CNS symptoms</td></tr><tr><td align="left" colspan="1" rowspan="1">Y114S</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">polyneuropathy, cardiomyopathy, carpal tunnel syndrome. others</td></tr><tr><td align="left" colspan="1" rowspan="1">G47V</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">polyneuropathy, autonomic dysfunction</td></tr><tr><td align="left" colspan="1" rowspan="1">S50R</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">autonomic dysfunction, others</td></tr><tr><td align="left" colspan="1" rowspan="1">V122I</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">cardiomyopathy, arrhythmia</td></tr><tr><td align="left" colspan="1" rowspan="1">V30A</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">ocular involvement</td></tr><tr><td align="left" colspan="1" rowspan="1">V30M/ K80R</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">A45V</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">polyneuropathy</td></tr><tr><td align="left" colspan="1" rowspan="1">T49I</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">cardiomyopathy, polyneuropathy</td></tr><tr><td align="left" colspan="1" rowspan="1">T49S</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">cardiomyopathy, carpal tunnel syndrome</td></tr><tr><td align="left" colspan="1" rowspan="1">V94G</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">autonomic dysfunction</td></tr><tr><td align="left" colspan="1" rowspan="1">A97G</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">polyneuropathy</td></tr><tr><td align="left" colspan="1" rowspan="1">A19D</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">V25S</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">polyneuropathy</td></tr><tr><td align="left" colspan="1" rowspan="1">V28M</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">polyneuropathy</td></tr><tr><td align="left" colspan="1" rowspan="1">V28S</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">autonomic dysfunction</td></tr><tr><td align="left" colspan="1" rowspan="1">F33V</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">ocular involvement</td></tr><tr><td align="left" colspan="1" rowspan="1">A36D</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">D38A</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">polyneuropathy</td></tr><tr><td align="left" colspan="1" rowspan="1">P43S</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">A45D</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">autonomic dysfunction</td></tr><tr><td align="left" colspan="1" rowspan="1">G53E</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">CNS symptoms</td></tr><tr><td align="left" colspan="1" rowspan="1">E54L</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">L55P</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">others</td></tr><tr><td align="left" colspan="1" rowspan="1">H56R</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">carpal tunnel syndrome</td></tr><tr><td align="left" colspan="1" rowspan="1">Y69H</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">CNS symptoms</td></tr><tr><td align="left" colspan="1" rowspan="1">S77Y</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">polyneuropathy</td></tr><tr><td align="left" colspan="1" rowspan="1">W79L</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">K80R</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">autonomic dysfunction</td></tr><tr><td align="left" colspan="1" rowspan="1">G83R</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">ocular involvement</td></tr><tr><td align="left" colspan="1" rowspan="1">E89D</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">E89K</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">E89Q</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">cardiomyopathy</td></tr><tr><td align="left" colspan="1" rowspan="1">R104H</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">renal impairment</td></tr><tr><td align="left" colspan="1" rowspan="1">Y105H</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">polyneuropathy</td></tr><tr><td align="left" colspan="1" rowspan="1">Y114H</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">polyneuropathy</td></tr><tr><td align="left" colspan="1" rowspan="1">A120S</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">carpal tunnel syndrome</td></tr><tr><td align="left" colspan="1" rowspan="1">V121A</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">others</td></tr></tbody></table><table-wrap-foot><p>This table presents information on the genotype, number of patients, and phenotype</p></table-wrap-foot></table-wrap>
</p><p id="Par22">The mean time from symptom onset to diagnosis in patients with ATTRv amyloidosis was also analyzed and stratified according to the mutation type. Patients with endemic V30M mutations experienced the shortest diagnostic delay (2.7&#8201;&#177;&#8201;1.7 years), whereas those with non-endemic V30M mutations and non-V30M mutations exhibited longer intervals (4.6&#8201;&#177;&#8201;4.5 years and 3.6&#8201;&#177;&#8201;3.7 years, respectively), reflecting differences in clinical presentation and diagnostic challenges (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref><bold>and</bold> Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par23">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Variability in onset to diagnosis intervals. The time from symptom onset to diagnosis is presented for 235 symptomatic ATTRv amyloidosis patients stratified by the <italic toggle="yes">TTR</italic> mutation type. Categories include V30M mutations in endemic and non-endemic areas and non-V30M mutations, highlighting diagnostic delays among subgroups</p></caption><graphic id="d33e918" position="float" orientation="portrait" xlink:href="13023_2025_4006_Fig4_HTML.jpg"/></fig>
</p><p id="Par24">Figure <xref rid="Fig5" ref-type="fig">5</xref> presents the mean diagnostic delays for patients with ATTRv amyloidosis stratified by initial symptoms. The shortest time to diagnosis was observed in patients with renal impairment (0.4&#8201;&#177;&#8201;0.1 years), whereas patients presenting with carpal tunnel syndrome experienced the longest delay (4.9&#8201;&#177;&#8201;2.8 years). Other notable delays included 4.6&#8201;&#177;&#8201;3.9 years for polyneuropathy and 2.9&#8201;&#177;&#8201;4.7 years for cardiomyopathy (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>).</p><p id="Par25">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Impact of initial symptoms on diagnosis timing. This figure analyzes the diagnostic intervals in 235 symptomatic patients with ATTRv amyloidosis, based on their initial symptoms. Categories include carpal tunnel syndrome, polyneuropathy, and other symptoms, showing the influence of clinical presentation on diagnostic delays</p></caption><graphic id="d33e937" position="float" orientation="portrait" xlink:href="13023_2025_4006_Fig5_HTML.jpg"/></fig>
</p><p id="Par26">Histopathological analyses identified the gastrointestinal tract (28.6%, <italic toggle="yes">n</italic>&#8201;=&#8201;60), heart (25.2%, <italic toggle="yes">n</italic>&#8201;=&#8201;53), and abdominal fat (19.5%, <italic toggle="yes">n</italic>&#8201;=&#8201;41) as the most common biopsy sites. Most sites demonstrated high positivity rates, with the nerves, vitreous body, and ligamentum carpi transversum achieving 100% positivity. Detection rates of amyloid deposits were similarly high in the gastrointestinal tract (88%), heart (98%), and abdominal fat (95%), reflecting the diagnostic utility of these biopsy sites (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par27">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Biopsy sites and amyloid deposit positivity rates</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Biopsy sites</th><th align="left" colspan="1" rowspan="1">Number</th><th align="left" colspan="1" rowspan="1">Positive</th><th align="left" colspan="1" rowspan="1">Negative</th><th align="left" colspan="1" rowspan="1">Positive rate (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gastrointestinal tract</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">7</td><td align="left" colspan="1" rowspan="1">88</td></tr><tr><td align="left" colspan="1" rowspan="1">Heart</td><td align="left" colspan="1" rowspan="1">53</td><td align="left" colspan="1" rowspan="1">52</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">98</td></tr><tr><td align="left" colspan="1" rowspan="1">Abdominal fat</td><td align="left" colspan="1" rowspan="1">41</td><td align="left" colspan="1" rowspan="1">39</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">95</td></tr><tr><td align="left" colspan="1" rowspan="1">Nerve</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">14</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">100</td></tr><tr><td align="left" colspan="1" rowspan="1">Vitreous body</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">100</td></tr><tr><td align="left" colspan="1" rowspan="1">Skin</td><td align="left" colspan="1" rowspan="1">13</td><td align="left" colspan="1" rowspan="1">12</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">92</td></tr><tr><td align="left" colspan="1" rowspan="1">Ligamentum carpi transversum</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">4</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">100</td></tr><tr><td align="left" colspan="1" rowspan="1">Meninges</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">100</td></tr><tr><td align="left" colspan="1" rowspan="1">Kidney</td><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">67</td></tr><tr><td align="left" colspan="1" rowspan="1">Prostate</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">100</td></tr><tr><td align="left" colspan="1" rowspan="1">Lip</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">100</td></tr><tr><td align="left" colspan="1" rowspan="1">Salivary glands</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">100</td></tr><tr><td align="left" colspan="1" rowspan="1">Ligamentum flavum</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">100</td></tr><tr><td align="left" colspan="1" rowspan="1">Muscle</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">100</td></tr></tbody></table><table-wrap-foot><p>This table presents the distribution of the positivity rates for amyloid deposits across various biopsy sites</p></table-wrap-foot></table-wrap>
</p><p id="Par28">Among the 57 patients diagnosed with ATTRv amyloidosis from 2020 to 2023, serum M-protein was measured in 30 patients and serum FLCs was measured in 28 patients.</p><p id="Par29">Monoclonal protein with lambda light chain and a reduced FLC &#954;/&#955; ratio (0.15) was identified in one patient with Y114H. In addition, 99mTc-PYP scintigraphy was performed in 24 patients. Among them, 23 patients showed 99mTc-PYP-positive uptake in the heart, while one patient with Y114C showed 99mTc-PYP-negative uptake in the heart.</p></sec><sec id="Sec7"><title>Discussion</title><p id="Par30">This retrospective, single-center study revealed that patients with V30M mutations in non-endemic areas and non-V30M mutations were more common than previously reported. Clinical characteristics differed between V30M patients in endemic and non-endemic areas as well as in non-V30M patients. Endemic V30M cases were diagnosed earlier because of the higher prevalence of family history and periodic monitoring. In contrast, non-endemic V30M and non-V30M patients, often lacking a family history, were frequently misdiagnosed. Additionally, patients with carpal tunnel syndrome (CTS) or polyneuropathy at onset experienced longer diagnostic delays. Understanding these differences is crucial for early diagnosis and timely intervention, particularly, given the availability of disease-modifying therapies.</p><p id="Par31">ATTRv amyloidosis, previously thought to be confined to endemic regions, is now known to affect both endemic and non-endemic areas worldwide [<xref ref-type="bibr" rid="CR2">2</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. In this study, 46 <italic toggle="yes">TTR</italic> mutations were detected in 235 symptomatic patients, compared to 25 mutations identified in 104 patients over a 5-year period in our earlier study. These findings highlight the increasing potential of diagnosing additional cases in Japan [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par32">Clinical characteristics varied among patients with V30M mutations in endemic and non-endemic areas and those with non-V30M mutations. Endemic V30M cases exhibited early-onset, high penetrance, and female predominance, whereas non-endemic V30M cases showed late-onset, low penetrance, and male predominance. Non-V30M cases presented with diverse symptoms, late-onset, low penetrance, and male predominance. The causes of these differences remain unclear but are likely influenced by multiple factors. First, the geographic origin of the <italic toggle="yes">TTR</italic> V30M mutation may affect disease onset and penetrance, with early onset and high penetrance observed in Portugal and Japanese endemic regions, and late onset and low penetrance seen in Sweden and non-endemic areas of Japan [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Second, mutations in non-coding regions of the TTR gene may regulate gene expression and influence both the age at onset and the clinical phenotype spectrum. Third, sex differences may contribute to phenotypic variation, as cardiac involvement is more frequently observed in male patients with non-endemic V30M or non-V30M mutations. Additionally, maternal inheritance may be associated with an earlier age at onset and higher disease penetrance [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par33">Possible explanations include differences in pathology: early-onset cases exhibit small-fiber and neuronal cell loss with amyloid deposition in the sympathetic ganglia, whereas late-onset cases show preserved unmyelinated fibers and amyloid deposition in the dorsal root ganglia [<xref ref-type="bibr" rid="CR20">20</xref>]. Phenotypic differences may also be related to TTR fragmentation; late-onset cases contain C-terminal TTR fragments in amyloid deposits, whereas early-onset cases have only full-length TTR [<xref ref-type="bibr" rid="CR23">23</xref>]. Additionally, the stability of variant TTR and ERAD mechanisms play a role, as destabilized variants such as A25T can bypass ERAD with T4 chaperoning, leading to CNS-selective amyloidosis [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par34">Patients with ATTR V30M amyloidosis in endemic areas were diagnosed earlier than those in non-endemic areas and patients with non-V30M amyloidosis, consistent with findings from a global survey [<xref ref-type="bibr" rid="CR25">25</xref>]. Early diagnosis in endemic areas is attributed to the high prevalence of family history and regular monitoring of at-risk family members, which facilitate timely detection [<xref ref-type="bibr" rid="CR26">26</xref>]. In contrast, patients with non-endemic V30M and non-V30M rarely have a family history, complicating early diagnosis. These cases are frequently misdiagnosed as CIDP, diabetic neuropathy, or lumbar canal stenosis, highlighting the need for increased clinical awareness to improve diagnostic accuracy [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p id="Par35">This study has few limitations. It relied on retrospective data from a single referral center with a limited number of patients. Moreover, the cohort included more cases of V30M in non-endemic areas and non-V30M mutations than V30M mutations in endemic areas, reflecting higher referral rates from specialists in non-endemic regions.</p><p id="Par36">In conclusion, this study highlights the genetic and clinical diversity of patients with ATTRv amyloidosis. Patients with V30M in non-endemic areas and non-V30M mutations were more prevalent than expected, with observed variations in clinical features and diagnostic timelines based on the mutation type and initial symptoms.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Dr. Nomura had full access to all study data and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Nomura, Ueda. Acquisition, analysis, or interpretation of data: Nomura, Misumi, Ueda. Drafting of the manuscript: Nomura, Ueda. Critical revision of the manuscript for important intellectual content: Misumi, Tasaki, Obayashi, Yamashita, Ando, Ueda. Statistical analysis: Nomura, Misumi. Funding acquisition: Nomura. Administrative, technical, or material support: Misumi, Tasaki, Obayashi, Yamashita, Ueda. Supervision: Ando, Ueda.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by a grant from Alnylam Pharmaceuticals.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in this published article.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par37">The studies involving human participants were approved by the Human Ethics Review Committee of Kumamoto University (Approval Nos. 450 and 1916). Informed consent was obtained from all patients prior to their participation in the study.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par38">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par39">Drs. Misumi and Ando reported receiving grants from Alnylam and Pfizer outside the submitted work. Dr. Tasaki reported receiving grants from Pfizer outside the submitted work. Dr. Ueda reported receiving grants and personal fees from Alnylam and Pfizer outside the submitted work. No other disclosures were reported.</p></notes><notes id="FPar4"><title>Clinical trial number</title><p id="Par40">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name><name name-style="western"><surname>Adams</surname><given-names>D</given-names></name><name name-style="western"><surname>Benson</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis</article-title><source>Amyloid</source><year>2022</year><volume>29</volume><fpage>143</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">35652823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13506129.2022.2052838</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ando Y, Adams D, Benson MD, et al. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022;29:143&#8211;55.<pub-id pub-id-type="pmid">35652823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13506129.2022.2052838</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrade</surname><given-names>C</given-names></name></person-group><article-title>A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves</article-title><source>Brain</source><year>1952</year><volume>75</volume><issue>3</issue><fpage>408</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">12978172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/75.3.408</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408&#8211;27.<pub-id pub-id-type="pmid">12978172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/75.3.408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araki</surname><given-names>S</given-names></name><name name-style="western"><surname>Mawatari</surname><given-names>S</given-names></name><name name-style="western"><surname>Ohta</surname><given-names>M</given-names></name><etal/></person-group><article-title>Polyneuritic amyloidosis in a Japanese family</article-title><source>Arch Neurol</source><year>1968</year><volume>18</volume><issue>6</issue><fpage>593</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">5652991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.1968.00470360015001</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Araki S, Mawatari S, Ohta M, et al. Polyneuritic amyloidosis in a Japanese family. Arch Neurol. 1968;18(6):593&#8211;602.<pub-id pub-id-type="pmid">5652991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.1968.00470360015001</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersson</surname><given-names>R</given-names></name></person-group><article-title>Familial amyloidosis with polyneuropathy. A clinical study based on patients living in Northern Sweden</article-title><source>Acta Med Scand Suppl</source><year>1976</year><volume>590</volume><fpage>1</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">1064291</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Andersson R. Familial amyloidosis with polyneuropathy. A clinical study based on patients living in Northern Sweden. Acta Med Scand Suppl. 1976;590:1&#8211;64.<pub-id pub-id-type="pmid">1064291</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tawara</surname><given-names>S</given-names></name><name name-style="western"><surname>Nakazato</surname><given-names>M</given-names></name><name name-style="western"><surname>Kangawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Identification of amyloid prealbumin variant in Familial amyloidotic polyneuropathy (Japanese type)</article-title><source>Biochem Biophys Res Commun</source><year>1983</year><volume>116</volume><issue>3</issue><fpage>880</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">6651852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-291x(83)80224-1</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Tawara S, Nakazato M, Kangawa K, et al. Identification of amyloid prealbumin variant in Familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun. 1983;116(3):880&#8211;8.<pub-id pub-id-type="pmid">6651852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0006-291x(83)80224-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>M</given-names></name><name name-style="western"><surname>Misumi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan</article-title><source>J Neurol</source><year>2018</year><volume>265</volume><issue>1</issue><fpage>134</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">29177547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-017-8640-7</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Yamashita T, Ueda M, Misumi Y, et al. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan. J Neurol. 2018;265(1):134&#8211;40.<pub-id pub-id-type="pmid">29177547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-017-8640-7</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Mutations in transthyretin gene (TTR). [Mutations in hereditary amyloidosis website]. Available at: <ext-link ext-link-type="uri" xlink:href="http://amyloidosismutations.com/mut-attr.php">http://amyloidosismutations.com/mut-attr.php</ext-link>. Accessed November 27, 2024.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koike</surname><given-names>H</given-names></name><name name-style="western"><surname>Misu</surname><given-names>K</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>S</given-names></name><etal/></person-group><article-title>Study group for hereditary neuropathy in japan. Type I (transthyretin Met30) Familial amyloid polyneuropathy in japan. early- vs late-onset form</article-title><source>Arch Neurol</source><year>2002</year><volume>59</volume><issue>11</issue><fpage>1771</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12433265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.59.11.1771</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Koike H, Misu K, Ikeda S, et al. Study group for hereditary neuropathy in japan. Type I (transthyretin Met30) Familial amyloid polyneuropathy in japan. early- vs late-onset form. Arch Neurol. 2002;59(11):1771&#8211;6.<pub-id pub-id-type="pmid">12433265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archneur.59.11.1771</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Concei&#231;&#227;o</surname><given-names>I</given-names></name><name name-style="western"><surname>De Carvalho</surname><given-names>M</given-names></name></person-group><article-title>Clinical variability in type I Familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal</article-title><source>Muscle Nerve</source><year>2007</year><volume>35</volume><issue>1</issue><fpage>116</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16969832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.20644</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Concei&#231;&#227;o I, De Carvalho M. Clinical variability in type I Familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve. 2007;35(1):116&#8211;8.<pub-id pub-id-type="pmid">16969832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.20644</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>M</given-names></name><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name></person-group><article-title>Recent advances in transthyretin amyloidosis therapy</article-title><source>Transl Neurodegener</source><year>2014</year><volume>3</volume><fpage>19</fpage><pub-id pub-id-type="pmid">25228988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2047-9158-3-19</pub-id><pub-id pub-id-type="pmcid">PMC4165622</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.<pub-id pub-id-type="pmid">25228988</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/2047-9158-3-19</pub-id><pub-id pub-id-type="pmcid">PMC4165622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benson</surname><given-names>MD</given-names></name></person-group><article-title>Liver transplantation and transthyretin amyloidosis</article-title><source>Muscle Nerve</source><year>2013</year><volume>47</volume><issue>2</issue><fpage>157</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">23169427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.23521</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Benson MD. Liver transplantation and transthyretin amyloidosis. Muscle Nerve. 2013;47(2):157&#8211;62.<pub-id pub-id-type="pmid">23169427</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mus.23521</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamashita</surname><given-names>T</given-names></name><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>S</given-names></name><etal/></person-group><article-title>Long-term survival after liver transplantation in patients with Familial amyloid polyneuropathy</article-title><source>Neurology</source><year>2012</year><volume>78</volume><issue>9</issue><fpage>637</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">22345221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e318248df18</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with Familial amyloid polyneuropathy. Neurology. 2012;78(9):637&#8211;43.<pub-id pub-id-type="pmid">22345221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e318248df18</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coelho</surname><given-names>T</given-names></name><name name-style="western"><surname>Maia</surname><given-names>LF</given-names></name><name name-style="western"><surname>Martins da Silva</surname><given-names>A</given-names></name><etal/></person-group><article-title>Tafamidis for transthyretin Familial amyloid polyneuropathy: a randomized, controlled trial</article-title><source>Neurology</source><year>2012</year><volume>79</volume><issue>8</issue><fpage>785</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22843282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182661eb1</pub-id><pub-id pub-id-type="pmcid">PMC4098875</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin Familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79(8):785&#8211;92.<pub-id pub-id-type="pmid">22843282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0b013e3182661eb1</pub-id><pub-id pub-id-type="pmcid">PMC4098875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berk</surname><given-names>JL</given-names></name><name name-style="western"><surname>Suhr</surname><given-names>OB</given-names></name><name name-style="western"><surname>Obici</surname><given-names>L</given-names></name><etal/></person-group><article-title>Diflunisal trial consortium. Repurposing diflunisal for Familial amyloid polyneuropathy: a randomized clinical trial</article-title><source>JAMA</source><year>2013</year><volume>310</volume><issue>24</issue><fpage>2658</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">24368466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2013.283815</pub-id><pub-id pub-id-type="pmcid">PMC4139164</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Berk JL, Suhr OB, Obici L, et al. Diflunisal trial consortium. Repurposing diflunisal for Familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310(24):2658&#8211;67.<pub-id pub-id-type="pmid">24368466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2013.283815</pub-id><pub-id pub-id-type="pmcid">PMC4139164</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>D</given-names></name><name name-style="western"><surname>Gonzalez-Duarte</surname><given-names>A</given-names></name><name name-style="western"><surname>O&#8217;Riordan</surname><given-names>WD</given-names></name><etal/></person-group><article-title>Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><issue>1</issue><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">29972753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1716153</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Adams D, Gonzalez-Duarte A, O&#8217;Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11&#8211;21.<pub-id pub-id-type="pmid">29972753</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1716153</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adams</surname><given-names>D</given-names></name><name name-style="western"><surname>Tournev</surname><given-names>IL</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>MS</given-names></name><etal/></person-group><article-title>HELIOS-A collaborators. Efficacy and safety of Vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial</article-title><source>Amyloid</source><year>2023</year><volume>30</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">35875890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13506129.2022.2091985</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Adams D, Tournev IL, Taylor MS, et al. HELIOS-A collaborators. Efficacy and safety of Vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1&#8211;9.<pub-id pub-id-type="pmid">35875890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/13506129.2022.2091985</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benson</surname><given-names>MD</given-names></name><name name-style="western"><surname>Waddington-Cruz</surname><given-names>M</given-names></name><name name-style="western"><surname>Berk</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Inotersen treatment for patients with hereditary transthyretin amyloidosis</article-title><source>N Engl J Med</source><year>2018</year><volume>379</volume><issue>1</issue><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">29972757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1716793</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22&#8211;31.<pub-id pub-id-type="pmid">29972757</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1716793</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dorbala</surname><given-names>S</given-names></name><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bokhari</surname><given-names>S</given-names></name><etal/></person-group><article-title>ASNC/AHA/ASE/EANM/ HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging</article-title><source>J Nucl Cardiol</source><year>2019</year><volume>26</volume><fpage>2065</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">31468376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12350-019-01760-6</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/ HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol. 2019;26:2065&#8211;123.<pub-id pub-id-type="pmid">31468376</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12350-019-01760-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naiki</surname><given-names>H</given-names></name><name name-style="western"><surname>Sekijima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics</article-title><source>Pathol Int</source><year>2020</year><volume>70</volume><issue>4</issue><fpage>191</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">31961039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pin.12902</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Naiki H, Sekijima Y, Ueda M, et al. Human amyloidosis, still intractable but becoming curable: the essential role of pathological diagnosis in the selection of type-specific therapeutics. Pathol Int. 2020;70(4):191&#8211;8.<pub-id pub-id-type="pmid">31961039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/pin.12902</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koike</surname><given-names>H</given-names></name><name name-style="western"><surname>Misu</surname><given-names>K</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pathology of early- vs late-onset TTR Met30 Familial amyloid polyneuropathy</article-title><source>Neurology</source><year>2004</year><volume>63</volume><issue>1</issue><fpage>129</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">15249622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000132966.36437.12</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Koike H, Misu K, Sugiura M, et al. Pathology of early- vs late-onset TTR Met30 Familial amyloid polyneuropathy. Neurology. 2004;63(1):129&#8211;38.<pub-id pub-id-type="pmid">15249622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000132966.36437.12</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohmori</surname><given-names>H</given-names></name><name name-style="western"><surname>Ando</surname><given-names>Y</given-names></name><name name-style="western"><surname>Makita</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of Familial amyloidotic polyneuropathy</article-title><source>J Med Genet</source><year>2004</year><volume>41</volume><issue>4</issue><fpage>e51</fpage><pub-id pub-id-type="pmid">15060127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.2003.014803</pub-id><pub-id pub-id-type="pmcid">PMC1735751</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Ohmori H, Ando Y, Makita Y, et al. Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of Familial amyloidotic polyneuropathy. J Med Genet. 2004;41(4):e51.<pub-id pub-id-type="pmid">15060127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jmg.2003.014803</pub-id><pub-id pub-id-type="pmcid">PMC1735751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>E</given-names></name><name name-style="western"><surname>Dias</surname><given-names>A</given-names></name><name name-style="western"><surname>Coelho</surname><given-names>T</given-names></name><etal/></person-group><article-title>Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability</article-title><source>J Neurol</source><year>2024</year><volume>271</volume><issue>9</issue><fpage>5746</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">38907862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-024-12509-8</pub-id><pub-id pub-id-type="pmcid">PMC11377651</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Carvalho E, Dias A, Coelho T, et al. Hereditary transthyretin amyloidosis: a myriad of factors that influence phenotypic variability. J Neurol. 2024;271(9):5746&#8211;61.<pub-id pub-id-type="pmid">38907862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00415-024-12509-8</pub-id><pub-id pub-id-type="pmcid">PMC11377651</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>M</given-names></name></person-group><article-title>Transthyretin: its function and amyloid formation</article-title><source>Neurochem Int</source><year>2022</year><volume>155</volume><fpage>105313</fpage><pub-id pub-id-type="pmid">35218869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuint.2022.105313</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Ueda M. Transthyretin: its function and amyloid formation. Neurochem Int. 2022;155:105313.<pub-id pub-id-type="pmid">35218869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neuint.2022.105313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekijima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wiseman</surname><given-names>RL</given-names></name><name name-style="western"><surname>Matteson</surname><given-names>J</given-names></name><etal/></person-group><article-title>The biological and chemical basis for tissue-selective amyloid disease</article-title><source>Cell</source><year>2005</year><volume>121</volume><issue>1</issue><fpage>73</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">15820680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2005.01.018</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Sekijima Y, Wiseman RL, Matteson J, et al. The biological and chemical basis for tissue-selective amyloid disease. Cell. 2005;121(1):73&#8211;85.<pub-id pub-id-type="pmid">15820680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2005.01.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dispenzieri</surname><given-names>A</given-names></name><name name-style="western"><surname>Coelho</surname><given-names>T</given-names></name><name name-style="western"><surname>Concei&#231;&#227;o</surname><given-names>I</given-names></name><etal/></person-group><article-title>THAOS investigators. Clinical and genetic profile of patients enrolled in the transthyretin amyloidosis outcomes survey (THAOS): 14-year update</article-title><source>Orphanet J Rare Dis</source><year>2022</year><volume>18</volume><issue>1</issue><fpage>236</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13023-022-02359-w</pub-id><pub-id pub-id-type="pmcid">PMC9206752</pub-id><pub-id pub-id-type="pmid">35717381</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Dispenzieri A, Coelho T, Concei&#231;&#227;o I, et al. THAOS investigators. Clinical and genetic profile of patients enrolled in the transthyretin amyloidosis outcomes survey (THAOS): 14-year update. Orphanet J Rare Dis. 2022;18(1):236.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13023-022-02359-w</pub-id><pub-id pub-id-type="pmcid">PMC9206752</pub-id><pub-id pub-id-type="pmid">35717381</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueda</surname><given-names>M</given-names></name><name name-style="western"><surname>Sekijima</surname><given-names>Y</given-names></name><name name-style="western"><surname>Koike</surname><given-names>H</given-names></name><etal/></person-group><article-title>Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies</article-title><source>J Neurol Sci</source><year>2020</year><volume>414</volume><fpage>116813</fpage><pub-id pub-id-type="pmid">32353608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2020.116813</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ueda M, Sekijima Y, Koike H, et al. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci. 2020;414:116813.<pub-id pub-id-type="pmid">32353608</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jns.2020.116813</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plant&#233;-Bordeneuve</surname><given-names>V</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>A</given-names></name><name name-style="western"><surname>Lalu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Diagnostic pitfalls in sporadic transthyretin Familial amyloid polyneuropathy (TTR-FAP)</article-title><source>Neurology</source><year>2007</year><volume>69</volume><issue>7</issue><fpage>693</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17698792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000267338.45673.f4</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Plant&#233;-Bordeneuve V, Ferreira A, Lalu T, et al. Diagnostic pitfalls in sporadic transthyretin Familial amyloid polyneuropathy (TTR-FAP). Neurology. 2007;69(7):693&#8211;8.<pub-id pub-id-type="pmid">17698792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000267338.45673.f4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cortese</surname><given-names>A</given-names></name><name name-style="western"><surname>Vegezzi</surname><given-names>E</given-names></name><name name-style="western"><surname>Lozza</surname><given-names>A</given-names></name><etal/></person-group><article-title>Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2017</year><volume>88</volume><issue>5</issue><fpage>457</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">28188196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2016-315262</pub-id><pub-id pub-id-type="pmcid">PMC5529976</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Cortese A, Vegezzi E, Lozza A, et al. Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry. 2017;88(5):457&#8211;8.<pub-id pub-id-type="pmid">28188196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jnnp-2016-315262</pub-id><pub-id pub-id-type="pmcid">PMC5529976</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>